Akash Tewari

Q: What is Akash Tewari's success rate?

Akash Tewari currently has a success rate of 58.862921541257506.

Q: What is the average return of Akash Tewari's calls?

Their stock ratings have generated an average return of 19.17297941024888.

Jefferies | Healthcare

Akash Tewari is an analyst from Jefferies specializing in the Healthcare sector. Ranked #2282 out of 4773 analysts, they have issued 10 stock ratings with a success rate of 58.86% and an average return of 19.17%.

With 10 ratings to date, Akash Tewari is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 58.86% and an average return of 19.17%, highlighting promising potential as their track record develops further.

#2282

Out of 4773

Total Ratings

+58.86%

Success Rate

+19.17%

Average Return

Recent Ratings Analysis

LTGO

Buy

Sep 01, 2026

Target

$50.00

Current

$22.15

Performance

-0.49%

Akash Tewari rated LTGO as Buy on Sep 01, 2026, setting a price target of 50. Shares have remained stable near 22.15, leaving the 50 target still in play.

DMRA

Buy

Jul 27, 2026

Target

$50.00

Current

$28.10

Performance

-4.55%

On Jul 27, 2026, DMRA was given a Buy rating by Akash Tewari, with a target price of 50. The stock traded sideways with a -4.55% move, keeping the bullish thesis unresolved.

IONS

Buy

Jul 09, 2026

Target

$90.00

Current

$54.21

Performance

-15.65%

IONS received a Buy rating from Akash Tewari on Jul 09, 2026, aiming for 90. The rating hasn’t played out as hoped, with the stock trading 15.65% below expectations.

APGE

Hold

Jun 24, 2026

Target

$135.00

Current

$135.07

Performance

1.79%

On Jun 24, 2026, Akash Tewari published a Hold outlook on APGE, with a target of 135. Sideways action left the Hold view intact, with no major move since 135.07.

LLY

Buy

Jun 09, 2026

Target

$1350.00

Current

$1115.25

Performance

-2.52%

Akash Tewari on Jun 09, 2026 assigned LLY a Buy rating, with a price target of 1350. The recommendation remains pending validation as shares consolidate around 1115.25.

SYRE

Buy

Apr 13, 2026

Target

$85.00

Current

$90.60

Performance

43.20%

On Apr 13, 2026, Akash Tewari reaffirmed SYRE with a Buy rating, targeting 85. The recommendation was supported by strong follow-through as the stock rose from 90.6 to 90.6.

VRTX

Buy

Mar 10, 2026

Target

$580.00

Current

$515.44

Performance

3.26%

VRTX was rated Buy by Akash Tewari on Mar 10, 2026, with a price objective of 580. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

AMGN

Hold

Mar 10, 2026

Target

$350.00

Current

$377.35

Performance

0.51%

On Mar 10, 2026, Akash Tewari initiated coverage on AMGN with a Hold rating and target of 350. The stock’s lack of movement around 377.35 aligned with a cautious approach.

GILD

Buy

Mar 10, 2026

Target

$180.00

Current

$143.72

Performance

-3.26%

Akash Tewari issued a Buy recommendation for GILD on Mar 10, 2026, price target set at 180. The target of 180 remains in play, though confirmation will depend on future moves.

BNTX

Buy

Mar 10, 2026

Target

$151.00

Current

$96.73

Performance

15.31%

On Mar 10, 2026, BNTX was evaluated by Akash Tewari, who gave a Buy rating and target of 151. This case illustrates how a timely bullish rating can translate into tangible gains of 15.31%.

REGN

Buy

Aug 27, 2025

Target

$831.00

Current

$781.49

Performance

33.14%

Akash Tewari rated REGN as Buy on Aug 27, 2025, setting a price target of 831. The call has proven timely, with shares rising 33.14% toward the price target of 831.

CBIO

Buy

Aug 25, 2025

Target

$26.00

Current

$19.41

Performance

32.04%

On Aug 25, 2025, CBIO was given a Buy rating by Akash Tewari, with a target price of 26. The stock rallied 32.04% after the rating, narrowing the gap to the target of 26 and validating the bullish stance.

BMY

Buy

Dec 16, 2024

Target

$70.00

Current

$63.64

Performance

13.91%

BMY received a Buy rating from Akash Tewari on Dec 16, 2024, aiming for 70. Momentum has favored the Buy call, with shares climbing from 63.64 to 63.64, rewarding those who trusted the recommendation.

BMRN

Buy

Nov 15, 2024

Target

$95.00

Current

$65.68

Performance

3.56%

On Nov 15, 2024, Akash Tewari published a Outperform outlook on BMRN, with a target of 95. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 65.68.

NBIX

Buy

Aug 19, 2024

Target

$189.00

Current

$156.22

Performance

5.38%

Akash Tewari on Aug 19, 2024 assigned NBIX a Buy rating, with a price target of 189. The Buy call aligned well with market performance, producing a gain of 5.38%.

APLS

Buy

Jul 31, 2024

Target

$80.00

Current

$41.03

Performance

3.61%

On Jul 31, 2024, Akash Tewari reaffirmed APLS with a Buy rating, targeting 80. Market indecision has kept the 80 target in a holding pattern.

Frequency Asked Questions

Who is Akash Tewari?

Akash Tewari is an analyst from Jefferies specializing in the Healthcare sector.

What is Akash Tewari's success rate?

Akash Tewari currently has a success rate of +58.86%.

How many ratings has Akash Tewari issued?

Akash Tewari has issued 10 stock ratings so far.

What is the average return of Akash Tewari's calls?

Their stock ratings have generated an average return of +19.17%.

What is Akash Tewari's ranking?

Akash Tewari is ranked #2282 out of 4773 analysts.

What types of ratings does Akash Tewari give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Akash Tewari?

You can follow Akash Tewari by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Akash Tewari?

Their latest rating was a Buy on LTGO issued on 2026-09-01.